Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair.

Guard SE, Poss ZC, Ebmeier CC, Pagratis M, Simpson H, Taatjes DJ, Old WM.

Sci Rep. 2019 Apr 25;9(1):6539. doi: 10.1038/s41598-019-42990-5.

2.

Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins.

Hennigan RF, Fletcher JS, Guard S, Ratner N.

Sci Signal. 2019 Apr 23;12(578). pii: eaau8749. doi: 10.1126/scisignal.aau8749.

PMID:
31015291
3.

In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants.

Hernando B, Swope VB, Guard S, Starner RJ, Choi K, Anwar A, Cassidy P, Leachman S, Kadekaro AL, Bennett DC, Abdel-Malek ZA.

Pigment Cell Melanoma Res. 2019 Mar;32(2):259-268. doi: 10.1111/pcmr.12732. Epub 2018 Sep 5.

PMID:
30117292
4.

Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study.

Kennelly M, Dmochowski R, Schulte-Baukloh H, Ethans K, Del Popolo G, Moore C, Jenkins B, Guard S, Zheng Y, Karsenty G; 191622-094 Investigators.

Neurourol Urodyn. 2017 Feb;36(2):368-375. doi: 10.1002/nau.22934. Epub 2015 Nov 24.

PMID:
26607743
5.

Efficacité et innocuité à long terme des injections répétées d'OnabotulinumtoxinA (BOTOX(®)) chez des patients souffrant d'hyperactivité du détrusor d'origine neurologique : résultats finaux d'un suivi longitudinal jusqu'à 4ans.

Karsenty G, Schulte-Baukloh H, Dmochowski R, Ethans K, Brenda J, Guard S, Zheng Y, Kennelly M.

Prog Urol. 2014 Nov;24(13):841. doi: 10.1016/j.purol.2014.08.128. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461654
6.

Le traitement par onabotulinumtoxin A (BOTOX(®)) améliore l'incontinence urinaire et la qualité de vie des patients porteurs d'hyperactivité Vésicale idiopathique indépendamment des infections urinaires ou du recours à l'autosondage.

Chartier-Kastler E, Everaert K, Gruenenfelder J, Schulte-Baukloh H, Guard S, Zheng Y, Sussman D.

Prog Urol. 2014 Nov;24(13):797-8. doi: 10.1016/j.purol.2014.08.036. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461561
7.

Characterisation of [125I][MePhe7]neurokinin B binding to tachykinin NK3 receptors: evidence for interspecies variance.

Suman-Chauhan N, Grimson P, Guard S, Madden Z, Chung FZ, Watling K, Pinnock R, Woodruff G.

Eur J Pharmacol. 1994 Sep 15;269(1):65-72.

PMID:
7530207
8.

Rational design of high affinity tachykinin NK1 receptor antagonists.

Boyle S, Guard S, Higginbottom M, Horwell DC, Howson W, McKnight AT, Martin K, Pritchard MC, O'Toole J, Raphy J, et al.

Bioorg Med Chem. 1994 May;2(5):357-70.

PMID:
7922147
9.

The non-peptide tachykinin NK2 receptor antagonist SR 48968 interacts with human, but not rat, cloned tachykinin NK3 receptors.

Chung FZ, Wu LH, Vartanian MA, Watling KJ, Guard S, Woodruff GN, Oxender DL.

Biochem Biophys Res Commun. 1994 Feb 15;198(3):967-72.

PMID:
8117304
10.

Rational design of high affinity tachykinin NK2 receptor antagonists.

Boyle S, Guard S, Hodgson J, Horwell DC, Howson W, Hughes J, McKnight A, Martin K, Pritchard MC, Watling KJ, et al.

Bioorg Med Chem. 1994 Feb;2(2):101-13.

PMID:
7922121
11.

Species variants of tachykinin receptor types.

Watling KJ, Guard S, Boyle SJ, McKnight AT, Woodruff GN.

Biochem Soc Trans. 1994 Feb;22(1):118-22. Review. No abstract available.

PMID:
7515828
12.

Receptor subtypes or species homologues: relevance to drug discovery.

Hall JM, Caulfield MP, Watson SP, Guard S.

Trends Pharmacol Sci. 1993 Oct;14(10):376-83. Review.

PMID:
8296394
13.
14.

The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences.

Guard S, Boyle SJ, Tang KW, Watling KJ, McKnight AT, Woodruff GN.

Br J Pharmacol. 1993 Sep;110(1):385-91.

15.
16.

On the presence of NK2 receptor subtypes in peripheral and central tissues.

Watling KJ, Guard S, Krause JE, Takeda Y, Quirion R, Zarnegar R, Pain D, Franks R.

Regul Pept. 1993 Jul 2;46(1-2):311-3. No abstract available.

PMID:
8210495
17.

[125I]neurokinin A labels pharmacologically distinct populations of NK2 binding sites in hamster and rabbit urinary bladder.

Guard S, Pain D, Franks R, Watling KJ.

Eur J Pharmacol. 1993 Mar 2;232(2-3):287-90. Erratum in: Eur J Pharmacol 1993 Jun 4;236(3):496.

PMID:
8385619
18.
19.

Tachykinin receptor types: Classification and membrane signalling mechanisms.

Guard S, Watson SP.

Neurochem Int. 1991;18(2):149-65.

PMID:
20504688
20.

Evidence for two types of tachykinin receptors on cholinergic neurons of the guinea pig ileum myenteric plexus.

Guard S, McKnight AT, Watling KJ, Watson SP.

Ann N Y Acad Sci. 1991;632:400-3. No abstract available.

PMID:
1719887
21.

Selective neurokinin receptor radioligands.

Quirion R, Dam TV, Guard S.

Ann N Y Acad Sci. 1991;632:137-44. Review. No abstract available.

PMID:
1659292
22.

Pharmacological characterization of tachykinin-stimulated inositol phospholipid hydrolysis in peripheral tissues.

Suman-Chauhan N, Guard S, Williams BJ, Watling KJ.

Br J Pharmacol. 1990 Dec;101(4):1001-5.

24.

Characterisation of [3H]-senktide binding to NK3 tachykinin receptors in guinea-pig ileum and cerebral cortex.

Guard S, Watling KJ, Watson SP.

Br J Pharmacol. 1989 Dec;98 Suppl:798P. No abstract available.

26.

Evidence for neurokinin-3 receptor-mediated tachykinin release in the guinea-pig ileum.

Guard S, Watson SP.

Eur J Pharmacol. 1987 Dec 15;144(3):409-12.

PMID:
2450037

Supplemental Content

Support Center